

Stempeutics bags US patent for osteoarthritis stem cell therapy

Stempeucel-OA is a cultured adult bone marrow-derived mesenchymal stromal cells and the patent covers covers methods associated with increasing levels of anti-inflammatory markers and decreasing levels of disease-progression markers in individuals with osteoarthritis.



Bengaluru: Stempeutics Research, a group company of Manipal Education and Medical Group, has announced to have secured US patent for a treatment approach using its stem cell-based drug Stempeucel-OA for osteoarthritis.

The patent covers an ultrasound-guided, intra-articular treatment with Stempeucel-OA administered before a single injection of mid-molecular-weight hyaluronic acid.

The patent covers an ultrasound-guided, intra-articular treatment with Stempeucel-OA administered before a single injection of mid-molecular-weight hyaluronic acid.

It also covers methods associated with increasing levels of anti-inflammatory markers and decreasing levels of disease-progression markers in individuals with osteoarthritis.

Stempeucel-OA is a single dose of 25 million ex vivo expanded, pooled, cultured adult human bone marrow-derived mesenchymal stromal cells. It is designed to act at the cellular level, helping reduce inflammation and pain, improve joint function.

In India, the therapy is marketed under the brands CiploStem by Cipla and StemOne by Alkem Laboratories.

“Our focus on innovation is guided by our strong sense of responsibility to address unmet patient needs and obtaining a US patent f is an important and historic milestone for Stempeutics. It sets a new benchmark in regenerative medicine, reflecting years of dedicated research and robust Phase 3 evidence,” said Manohar BN, MD & CEO of Stempeutics.

News Source:

<https://pharma.economictimes.indiatimes.com/news/pharma-industry/stempeutics-bags-us-patent-for-osteoarthritis-stem-cell-therapy/133227046>